Skip to main content

Normal FGF23 Levels in Adult Idiopathic Phosphate Diabetes

Calcified Tissue International volume 84, pages 112–117 (2009)Cite this article

Abstract

Fibroblast growth factor 23 (FGF23), a recently discovered phosphaturic substance playing a key role in genetic and oncogenic phosphate diabetes, is involved in the physiological regulation of phosphate metabolism. Moderate idiopathic phosphate diabetes (IPD) leading to male osteoporosis and diffuse pain resembling fibromyalgia has been described. The aim of our study was to define the role of FGF23 in the mechanism of IPD. The study concerned 29 patients with IPD, mean age 53 ± 11 years, of whom 72% were men. Fifteen subjects without bone disease and with normal serum phosphate and calcium levels were used as controls. Phosphate diabetes was confirmed by phosphate reabsorption level <85% and phosphate reabsorption threshold (TmPO4/GFR) <0.83. Known causes of phosphate diabetes were excluded. Fasting level of FGF23, serum phosphate, 1-25(OH)2D3, and parathyroid hormone were measured in patients and compared with FGF23 and serum phosphate in healthy controls. Spinal and hip bone mineral density (BMD) were measured by osteodensitometry. Sixteen of 29 patients had diffuse pain, 10 had osteoporosis according to the World Health Organization criteria, and 11 had osteopenia. Serum phosphate was significantly lower in patients than in controls, but FGF23 levels did not differ. Compared to patients with normal bone status, patients with osteopenia and osteoporosis had significantly decreased FGF23 levels, whereas serum phosphate was identical in the two groups. In all patients, serum phosphate and FGF23 were positively correlated and FGF23 and 1-25(OH)2D3 were negatively correlated. FGF23 seems not be a cause of IPD, and the FGF23/phosphate/1-25(OH)2D3 axis appeared to be functional.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

References

  1. Drezner MK (2000) PHEX gene and hypophosphatemia. Kidney Int 57:9–18

    PubMed  Article  CAS  Google Scholar 

  2. Econs MJ, McEnery PT (1997) Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab 82:674–681

    PubMed  Article  CAS  Google Scholar 

  3. Jan de Beur SM (2005) Tumor-induced osteomalacia. JAMA 294:1260–1267

    PubMed  Article  Google Scholar 

  4. de Vernejoul MC, Marie P, Kuntz D, Gueris J, Miravet L, Ryckewaert A (1982) Nonosteomalacic osteopathy associated with chronic hypophosphatemia. Calcif Tissue Int 34:219–223

    PubMed  Article  Google Scholar 

  5. Gerster JC, Jaeger P, Gobelet C, Boivin G (1986) Adult sporadic hypophosphatemic osteomalacia presenting as regional migratory osteoporosis. Arthritis Rheum 29:688–692

    PubMed  Article  CAS  Google Scholar 

  6. Laroche M, Arlet J, Ader JL, Durand D, Arlet P, Cantagrel A, Tran Van T, Mazieres B (1992) Male osteoporosis, an unrecognised etiology: moderate idiopathic proximal tubulopathy (MIPT) [in French]. Rev Rhum Mal Osteoartic 59:3–9

    PubMed  CAS  Google Scholar 

  7. Amor B, Clemente-Coelho PJ, Rajzbaum G, Poiraudeau S, Friedlander G (1995) Adult-onset idiopathic phosphate diabetes. I. Chronic pseudoinflammatory back pain and osteopenia. Rev Rhum Engl Ed 62:175–181

    PubMed  CAS  Google Scholar 

  8. Walton RJ, Bijvoet OL (1975) Nomogram for derivation of renal threshold phosphate concentration. Lancet 2:309–310

    PubMed  Article  CAS  Google Scholar 

  9. Gentil C, Paupe J, Schepens G, Antener I, Colin J, Satge P, Canlorbe P, Lelong M (1963) Idiopathic vitamin-resistant rickets: 5 cases with determination of the vitamin D activity of the serum. Critical review of the literature. Ann Pediatr 10:213–244 (Paris)

    CAS  Google Scholar 

  10. Land JM, Kemp GJ, Taylor DJ, Standing SJ, Radda GK, Rajagopalan B (1993) Oral phosphate supplements reverse skeletal muscle abnormalities in a case of chronic fatigue with idiopathic renal hypophosphatemia. Neuromuscul Disord 3:223–225

    PubMed  Article  CAS  Google Scholar 

  11. Laroche M, Tack Y (1999) Hypophosphoremia secondary to idiopathic moderate phosphate diabetes: a differential diagnosis with primary fibromyalgia. Clin Exp Rheumatol 17:628

    PubMed  CAS  Google Scholar 

  12. Berndt T, Kumar R (2007) Phosphatonins and the regulation of phosphate homeostasis. Annu Rev Physiol 69:341–359

    PubMed  Article  CAS  Google Scholar 

  13. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T (2001) Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 98:6500–6505

    PubMed  Article  CAS  Google Scholar 

  14. White KE, Evans WE, O’Riordan JLH, Speer MC, Econs MJ, Lorenz-Depiereux B, Grabowski M, Meitinger T, Strom TM (2000) Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26:345–348

    Article  CAS  Google Scholar 

  15. White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ (2001) Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 60:2079–2086

    PubMed  Article  CAS  Google Scholar 

  16. Ferrari SL, Bonjour JP, Rizzoli R (2005) Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 90:1519–1524

    PubMed  Article  CAS  Google Scholar 

  17. Nishida Y, Taketani Y, Yamanaka-Okumura H, Imamura F, Taniguchi A, Sato T, Shuto E, Nashiki K, Arai H, Yamamoto H, Takeda E (2006) Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. Kidney Int 70:2141–2147

    PubMed  CAS  Google Scholar 

  18. Schiavi SC (2006) Fibroblast growth factor 23: the making of a hormone. Kidney Int 69:425–427

    PubMed  Article  CAS  Google Scholar 

  19. Mirams M, Robinson BG, Mason RS, Nelson AE (2004) Bone as a source of FGF23: regulation by phosphate? Bone 35:1192–1199

    PubMed  Article  CAS  Google Scholar 

  20. Yoshiko Y, Wang H, Minamizaki T, Ijuin C, Yamamoto R, Suemune S, Kozai K, Tanne K, Aubin JE, Maeda N (2007) Mineralized tissue cells are a principal source of FGF23. Bone 40:1565–1573

    PubMed  Article  CAS  Google Scholar 

  21. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T (2006) Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444:770–774

    PubMed  Article  CAS  Google Scholar 

  22. Bai X, Miao D, Li J, Goltzman D, Karaplis AC (2004) Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 145:5269–5279

    PubMed  Article  CAS  Google Scholar 

  23. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T (2004) Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113:561–568

    PubMed  CAS  Google Scholar 

  24. Shimada T, Yamazaki Y, Takahashi M, Hasegawa H, Urakawa I, Oshima T, Ono K, Kakitani M, Tomizuka K, Fujita T, Fukumoto S, Yamashita T (2005) Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 289:F1088–F1095

    PubMed  Article  CAS  Google Scholar 

  25. Prie D, Blanchet FB, Essig M, Jourdain JP, Friedlander G (1998) Dipyridamole decreases renal phosphate leak and augments serum phosphate in patients with low renal phosphate threshold. J Am Soc Nephrol 9:1264–1269

    PubMed  CAS  Google Scholar 

  26. Rendina D, Mossetti G, De Filippo G, Cioffi M, Strazzullo P (2006) Fibroblast growth factor 23 is increased in calcium nephrolithiasis with hypophosphatemia and renal phosphate leak. J Clin Endocrinol Metab 91:959–963

    PubMed  Article  CAS  Google Scholar 

  27. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Juppner H (2003) Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348:1656–1663

    PubMed  Article  CAS  Google Scholar 

  28. Imel EA, Peacock M, Pitukcheewanont P, Heller HJ, Ward LM, Shulman D, Kassem M, Rackoff P, Zimering M, Dalkin A, Drobny E, Colussi G, Shaker JL, Hoogendoorn EH, Hui SL, Econs MJ (2006) Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J Clin Endocrinol Metab 91:2055–2061

    PubMed  Article  CAS  Google Scholar 

  29. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S (2002) Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87:4957–4960

    PubMed  Article  CAS  Google Scholar 

  30. Fukumoto S, Nakahara K (2004) Establishment of assay system for fibroblast growth factor (FGF)-23 and pathophysiological roles of FGF-23 in the development of hypophosphatemic diseases [in Japanese]. Rinsho Byori 52:51–54

    PubMed  CAS  Google Scholar 

  31. Berndt TJ, Craig TA, McCormick DJ, Lanske B, Sitara D, Razzaque MS, Pragnell M, Bowe AE, O’Brien SP, Schiavi SC, Kumar R (2007) Biological activity of FGF-23 fragments. Pflugers Arch 454:615–623

    PubMed  Article  CAS  Google Scholar 

  32. Burnett SM, Gunawardene SC, Bringhurst FR, Juppner H, Lee H, Finkelstein JS (2006) Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 21:1187–1196

    PubMed  Article  CAS  Google Scholar 

  33. Prie D, Huart V, Bakouh N, Planelles G, Dellis O, Gerard B, Hulin P, Benque-Blanchet F, Silve C, Grandchamp B, Friedlander G (2002) Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodium-phosphate cotransporter. N Engl J Med 347:983–991

    PubMed  Article  CAS  Google Scholar 

  34. Lapointe JY, Tessier J, Paquette Y, Wallendorff B, Coady MJ, Pichette V, Bonnardeaux A (2006) NPT2a gene variation in calcium nephrolithiasis with renal phosphate leak. Kidney Int 69:2261–2267

    PubMed  Article  CAS  Google Scholar 

Download references

Author information

Affiliations

  1. Service de Rhumatologie, CHU Rangueil, Toulouse, France

    M. Laroche & J. F. Boyer

  2. Service de Rhumatologie, Hopital Larrey, 24 chemin de Pouvourville, 31059, Toulouse Cedex 9, France

    M. Laroche

  3. Service d’Explorations Physiologiques Rénales, CHU Rangueil, Toulouse, France

    H. Jahafar, J. Allard & I. Tack

Authors
  1. M. Laroche
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. F. Boyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Jahafar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Allard
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. I. Tack
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Laroche.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Laroche, M., Boyer, J.F., Jahafar, H. et al. Normal FGF23 Levels in Adult Idiopathic Phosphate Diabetes. Calcif Tissue Int 84, 112–117 (2009). https://doi.org/10.1007/s00223-008-9204-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00223-008-9204-8

Keywords

  • Fibroblast growth factor 23
  • Idiopathic phosphate diabetes